PLGA-PEG-COOH from PolySciTech used in development of oral vaccine delivery

 

Delivery of vaccines by the oral pathway is complicated due to damage in the stomach and poor oral uptake. Researchers at University of Kansas used PLGA-PEG-COOH (AI166) and PLGA (AP121) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to develop nanoparticles for vaccine delivery. This research holds promise to provide for improved vaccine delivery. Read more: Xie, Jin, Xiaodi Li, Grahmm A. Funk, Su Jeong Song, Udita Shah, Connor S. Ahlquist, and Hyunjoon Kim. "Immunostimulatory Pickering emulsion for oral vaccine delivery." International Journal of Pharmaceutics (2025): 125890. https://www.sciencedirect.com/science/article/pii/S0378517325007276

“To overcome gastric acid degradation and ensure robust immune activation, a novel Pickering emulsion stabilized by poly(lactic-co-glycolic acid) (PLGA) nanoparticles was developed for the co-delivery of vaccine antigens and adjuvants via the oral route. Pickering emulsions, stabilized by solid particles, can enhance stability and protect antigens from gastric degradation. We encapsulated a TLR7/8 agonist R848 in PLGA nanoparticles and fabricated Pickering emulsions (R848-PLGA-NP@PE) to boost immune activation, and further prepared model antigen Ovalbumin (OVA) loaded Pickering emulsion formulation (R848-PLGA-NP@PE-OVA) to induce antigen-specific immune responses. R848-PLGA-NPs can improve vaccine efficacy by serving both as a stabilizer and an adjuvant, activating antigen-presenting cells (APCs). R848-PLGA-NP@PE-OVA exhibited a uniform particle size (245 nm), stable zeta potential (−40 mV), and high antigen encapsulation efficiency (>80 %), that were tested in Simulated Intestinal Fluid (SIF) and Simulated Gastric Fluid (SGF). R848-PLGA-NP@PE exhibited enhanced uptake by and activation of dendritic cells compared to control groups. In vivo, R848-PLGA-NP@PE significantly improved CD4 + T cell, CD8 + T cell, and NK cell activation. Notably, granzyme B expression in NK cells reached 2.1 times the level of the PBS group and 1.45 times that of the Free OVA + R848 group. The OVA-specific IgG level in the R848-PLGA-NP@PE-OVA group was approximately 3.9 times that of the PBS group and 2.5 times that of the free R848 + OVA group. Fecal OVA-specific IgA levels were significantly higher than control group. The combined data suggests that Pickering emulsions fabricated with PLGA-NPs are versatile oral vaccine delivery platforms to induce cellular and humoral immune responses.”

PLGA (https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AP121#h)
PLGA-PEG-COOH (https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AI166#h)
Benchtop to Bedside with MidWest GMP https://www.akinainc.com/midwestgmp/
Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/
Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/
July 14-18: meet at 2025 CRS AM&E Poster #274
BPR Akina's Free Scientific Conference (West Lafayette, 9/30/25: (https://akinainc.com/bprconference/)